ProfileGDS5678 / 1428993_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 77% 73% 72% 69% 72% 73% 74% 72% 72% 71% 76% 69% 72% 72% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.1564377
GSM967853U87-EV human glioblastoma xenograft - Control 24.7289973
GSM967854U87-EV human glioblastoma xenograft - Control 34.5668572
GSM967855U87-EV human glioblastoma xenograft - Control 44.2907569
GSM967856U87-EV human glioblastoma xenograft - Control 54.5244972
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.681773
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.7981474
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.5354472
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.5677772
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.5118971
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.1222276
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.2999869
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.5827872
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.5701872